LRRK2 Cohort Consortium
The MJFF-led LRRK2 Cohort Consortium brought research groups together to speed efforts to move LRRK2 toward therapeutic relevance for patients.
The Consortium comprised three initiatives:
Each cohort includes LRRK2-positive Parkinson's patients, unaffected LRRK2 mutation carriers, idiopathic PD patients and control subjects. The Consortium contributed a common core dataset, and clinical data and biological samples are stored in a comprehensive Parkinson's database and biorepository.
Available Data and Biospecimens
MJFF makes data and biosamples available to the scientific community to conduct research on novel PD biomarkers. Biospecimens and data from the LRRK2 Cohort Consoritum (LCC) are available to qualified members of the research community.
Consortium biosamples are available through a collaborative resource access program with the National Institute for Neurological Disorders and Stroke (NINDS). Learn more and request access.
We also fund promising projects that use MJFF data and biospecimen collections. Submit a proposal budget using the proper template ( Industry/For Profit or Academic/Non-profit ) to email@example.com for review in parallel with the sample application submitted to NINDS.
LRRK2 Cohort Consortium Publications
Analysis from the LRRK2 Cohort Consortium has yielded notable findings. View a list of all publications and presentations from projects utilizing the resources.
Ongoing Research Utilizing LRRK2 Cohort Consortium Specimens
The following research studies have accessed LRRK2 Cohort Consortium samples. Researchers may apply to use biospecimens through NINDS .
|Project Title||Principal Investigator||Institution||Specimen(s) Used|
|Influence of Immune Subtypes on the LRRK2 Phenotype||Daniela Berg, MD||Centre of Neurology and Hertie-Institute for Clinical Brain Research, University Hospital Tuebingen||Plasma|
|Peripheral blood-based gene transcript biomarkers for prediction of Parkinson disease in LRRK2 mutation carriers||Avi Orr-Urtreger MD, PhD||Tel Aviv Sourasky Medical Center||
|Alpha-synuclein and other biomarkers in biological samples of LRRK2 PD||Eduardo Tolosa, MD, PhD||Hospital Clinic Universitari de Barcelona||CSF|
|Effect of LRRK2 mutations on PD-associated inflammation||Nicolas Dzamko, PhD||Neuroscience Research Australia||CSF, serum|
|aSyn 3'UTR modulation in LRRK2 carriers as a potential biomarker||Asa Abeliovich, MD, PhD||Columbia University Medical Center||RNA|
|LRRK2 in urine as a biomarker for PD||Andrew West, PhD||University of Alabama, Birmingham||Urine|
|Purine biomarkers of LRRK2 PD||Michael Schwarzschild, MD, PhD||Mass General Institute for Neurodegenerative Disease||Plasma|
|Analysis of A-beta, tau and p-tau in CSF samples from the LRRK2 Cohort Consortia||Leslie Shaw MD, PhD||University of Pennsylvania||CSF|
|NeuroX Profiling of Samples from the PPMI Prodromal and Genetic Cohorts, the LRRK2 Cohort Consortium, and the BioFIND Cohort||Andrew Singleton PhD||National Institute on Aging||DNA|
|Whole exome sequencing and analysis of PPMI Prodromal and Genetic Cohorts, PPMI Genetic Registry, and LRRK2 Cohort Consortium samples||Andrew Singleton PhD||National Institute on Aging||DNA|
|Biomarkers of the Glucocerebrosidase Pathway in Parkinson Disease||Rachel Saunders-Pullman MD, MPH, MS||Icahn School of Medicine at Mount Sinai||CSF, Plasma|
|MicroRNAs as biomarkers of the prodromal stage of Parkinson disease||Mario Ezquerra PhD||Barcelona Clinic||Urine|
|LRRK2 biomarker initiative- Detection of LRRK2 in cerebral spinal fluid and urine||Jean-Marc Taymans PhD||INSERM||Urine|
Have a Question?